New radioactive cocktail shows promise for tough prostate cancers
Disease control
Completed
This study tested a radioactive drug (I-131-1095) plus a standard hormone therapy (enzalutamide) in 120 men with advanced prostate cancer that had stopped responding to another treatment (abiraterone). The goal was to see if the combination could shrink tumors and lower PSA level…
Phase: PHASE2 • Sponsor: Progenics Pharmaceuticals, Inc. • Aim: Disease control
Last updated May 05, 2026 11:54 UTC